ACE2 / TMPSS2 / S Protein:
COVID19 virus attached human cells via two cell surface target, ACE2 and the serine protease, TMPRSS2, through its Spike (S) Protein. To facilitate the research for the treatment of COVID-19, Gentarget now provides the expression lentivirus products for human ACE2 (CAT#: LVP1310), TMPSS2 (CAT#: LVP1309), and Spike (S) (CAT#: LVP1329 ), S1-RBD (CAT#: LVP1330), and ACE2 high expression stable cell lines (SC075, SC076), as well as the VLP (Virial Like Particle) for S protein (CAT#: VLP001)
What the products used for:
The ACE2 and TMPRSS2 lentivirus can be used for the validation assay for vaccine, antibody or drug efficacy. The S protein contains two subunits: S1 and S2. It is the target for vaccines, therapeutic antibodies, and diagnostics. The S protein lentivirus (CAT#: LVP1329) express the human codon optimized COVID-19’s Spike protein containing the C-terminal 6His tag. It can be used to express and purify the S protein as antigen for assay validation or for antibody production. Those products contain a internal RFP fluorescent marker as well as the blasticidin selection which makes easier to generate their expression cell lines if desired.
The ACE2 expression stable cell lines can be used for in vitro screening and characterization of antibodies, vaccines, or drug candidates against SARS-CoV, COVID-19 coronavirus.
The S-VLP product it the S protein pseudotyped lentiviral particles in which the S protein mimic its native virus surface confirmation. It is best suited for screening of the most effective anti-COVID 19 antibody or vaccine.